Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective

Bibliography

• REYNOLDS GP: What is an atypical antipsychotic? J. Psychopharmacol. (1997) 11:195–199.
   Google Scholar
• •A review of the concept of atypicality, its experimental models and correlates and the proposed pharmacological mechanisms that may contribute to it.
   Google Scholar
• REYNOLDS GP: The new antipsychotics - some pharmacological aspects of their problems and potential. Exp. Opin. Pharmacother. (2000) 1 (2):181–185.
   PubMedGoogle Scholar
• •A brief review of the possible pharmacological bases for the effects of the newer antipsychotics on EPS, weight gain, negative symptoms, depressive symptoms and cognitive function in schizophrenia.
   Google Scholar
• BUSATTO GF, KERWIN RW: Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J. Psychopharmacol (1997) 11:3–12.
   PubMedGoogle Scholar
• •An assessment of the contribution of effects at 5-HT receptors on the mechanisms of antipsychotic drug action, in the context of recent genetic and imaging studies.
   Google Scholar
• KALKMAN HO, NEUMANN V, HOYER D, TRICKLEBANK MD: The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br. J. Pharmacol. (1998) 124:1550–1556.
   PubMedGoogle Scholar
• REYNOLDS GP: Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta PsychiaL Scand. (1994) 89 (Suppl. 380):36–40.
   Google Scholar
• SEEMAN P, TALLERICO T: Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J PsychiaL (1999) 156:876–884.
   PubMed Web of Science ®Google Scholar
• •An interesting hypothesis relating weak effects of antipsy-chotics at the D2 receptor to aspects of atypicality.
   Google Scholar
• FRIEDMAN JH, FACTOR SA: Atypical antipsychotics in the treatment of drug-induced psychosis in Parkin-son's disease. Mov. Dis. (2000) 15:201–211.
   PubMed Web of Science ®Google Scholar
• •A critical review of published reports of trials of the newer antipsychotic drugs (i.e., clozapine, quetiapine, olanzapine and risperidone) in the treatment of psychosis in Parkinson's disease.
   Google Scholar
• LEVY ML, CUMMINGS JL, KAHN-ROSE R: Neuropsychi-atric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology (1999) 45 (Suppl. 1):15–22.
   Google Scholar
• MCSHANE R, KEENE J, GEDLING K, FAIRBURN C, JACOBY R, HOPE T: Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. Br. Med. J. (1997) 314:266–270.
   PubMed Web of Science ®Google Scholar
• •An intriguing observation that cognitive decline is acceler-ated in demented patients receiving classical antipsychotics.
   Google Scholar
• STOPPE G, BRANDT CA, STAEDT JH: Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs Aging (1999) 14:41–54.
   PubMedGoogle Scholar
• •A useful review assessing the relative values of the use of novel antipsychotics in dementia.
   Google Scholar
• STREET JS, CLARK WS, GANNON KS et al: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. PsychiaL (2000) 57:968–976.
   PubMed Web of Science ®Google Scholar
• DE DEYN PP, RABHERU K, RASMUSSEN A et al.: A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology (1999) 5 3 :946–955.
   Google Scholar
• KATZ IR, JESTE DV, MINTZER JE et al.: Comparison ofrisperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomised, double-blind trial. J. Clin. Psychiatry (1999) 60:107–115.
   PubMed Web of Science ®Google Scholar
• MCKEITH I, FAIRBAIRN A, PERRY R, THOMPSON P, PERRYE: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br. Med. J. (1992) 305:673–678.
   PubMed Web of Science ®Google Scholar
• PERRY EK, MARSHALL E, THOMPSON P et al.: Monoamin-ergic activities in Izwy body dementia: relation to hallucinosis and ex tr apyramidal features. J Neural Transm. (1993) 6:167–177.
   Web of Science ®Google Scholar
• MCKEITH I, DEL SER T, SPANO PF et al.: Efficacy of rivastigrnine in dementia with Izwy bodies: a random-ised, double-blind, placebo controlled international study. Lancet (2000) 356:2031–2036.
   PubMed Web of Science ®Google Scholar
• WALKER Z, GRACE J, OVERSHOT R et al.: Olanzapine in dementia with Iewy bodies: a clinical study. Int. J Geriatr. PsychiaL (1999) 14:459–466.
   PubMed Web of Science ®Google Scholar
• PANTELIS C, BARNES TRE, NELSON HE: Is the concept of frontal-subcortical dementia relevant to schizo-phrenia? Br. J PsychiaL (1992) 160:442–460.
   PubMedGoogle Scholar
• COLLABORATIVE WORKING GROUP ON CLINICAL TRIAL EVALUATIONS: Evaluating the effects of antipsychotics on cognition in schizophrenia. J Clin. PsychiaL (1998) 59 (Suppl. 12):35–40.
   Google Scholar
• MAYER-LINDENBERG A, GRUPPE H, BAUER U, LIS S, KRIEGER S, GALLHOFER B: Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatty (1997) 30:35–42.
   Google Scholar
• BOWEN DM, FRANCIS PT, PANGALOS MN, STEPHENS PH, PROCTOR AW: Treatment strategies for Alzheimer's disease. Lancet (1992) 339:132.
   PubMed Web of Science ®Google Scholar
• •This letter noted the effects of 5-HTIA drugs on cortical glutamatergic neurones and indicated a possible clinical application.
   Google Scholar
• JESTE DV, OKAMOTO A, NAPOLITANO J et al.: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am../ Psychiatry (2000) 157:1150–1155.
   PubMedGoogle Scholar
• •An open-label demonstration of the low incidence of tardive dyskinesia with low-dose risperidone in dementia.
   Google Scholar
• DAVIS KL, SAMUELS SC: Dementia and delerium. In: Pharmacological Management of Neurological and Psychi-atric Disorders. Enna SJ, Coyle JT (Eds.) McGraw-Hill, New York (1998) :267–316.
   Google Scholar
• •A valuable summary of the pharmacological management of dementing disorders, putting pharmacology in the context of the neurobiology of these conditions.
   Google Scholar